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Mathematical approach used in the current meta-analysis
The approach to meta-analysis and all formulae in this document are based on the method of Hedges' et al. (Borenstein et al. 2009 ).
Combining of data from independent (active rTMS) subgroups within studies
Some studies in the current meta-analysis compared one sham group with more than one active rTMS groups. Thus, for the purposes of the overall meta-analysis the data from the multiple active subgroups were combined into one active rTMS group to compute only one effect size for the study. Using one example study (Padberg et al. 1999) , the mean (M) and standard deviation (SD) of depression scores for the two active subgroups (stimulation frequencies of either 10 Hz or .3 Hz) were combined into one group at each of the two points in time (pre and post-treatment) according to the following formulae (Borenstein et al. 2009 p. 222):
• The combined mean depression score for the 'active-pre' group (M 1+2 ) was computed by weighing the mean depression score of subgroup 1 (M 1 ; 10 Hz) and subgroup 2 (M 2 ; .3 Hz) based on the sample size of each subgroup (N 1 and N 2 ):
The combined mean depression score for the other group ('active-post') was computed the same way.
• The combined standard deviation of the mean depression scores for the 'active-pre' group (SD 1+2 ) was computed using individual SD and N values of subgroup 1 (10 Hz; SD 1 and N 1 ) and subgroup 2 (.3 Hz; SD 2 and N 2 ):
The combined standard deviation of the mean depression scores for the other group ('active-post') was computed the same way.
• The combined sample size for the 'active-pre' group (N 1+2 ) was computed by adding the sample sizes of the two subgroups (N 1 + N 2 ). The combined sample size for the other group ('active-post') was computed the same way.
The study by Stern and colleagues (Stern et al. 2007 ), was performed on three active subgroups (10 Hz left DLPFC, 1 Hz left DLPFC, and 1 Hz right DLPFC). Thus, the two left-stimulation subgroups (10 Hz and 1 Hz) were combined first and these (combined) scores were then combined with the scores of the rightstimulation subgroup according to the formulae described above.
Combining of data in dependent subgroups at different points in time (pre and post)
Since data were collected from the same groups (sham or active) twice (pre and post treatment) it was necessary to reduce them to one score/group for the purposes of meta-analysis. Following the approach of Holtzheimer and colleagues (Holtzheimer et al. 2001) , such reduction in scores was performed by expressing the severity of depression scores as difference scores: mean depression at baseline (pretreatment) -last session (post-treatment) in each group separately (M S in sham or M A in active groups).
The total sample size N of each group (N S or N A ) was either the sample size at baseline or the mean sample size at baseline and last session if any patients dropped out of the study.
The SD of the mean difference scores was computed for each group separately (SD S or SD A ) as follows (Borenstein et al. 2009 p. 234 ):
The correlation coefficient r=.5, between the pre-and the post-treatment depression scores, was chosen as the most optimal coefficient that neither overestimates the SD (r=.0) nor underestimates the SD (r=1.0) (Borenstein et al. 2009 p. 237, (Borenstein et al. 2009 p. 27 ):
In addition to d, the standardised mean difference, Hedges' g (that is an unbiased version of d in small-N studies) and its variance (V g ) were computed for the sham and active stimulation groups in each study as follows (Borenstein et al. 2009 p. 27 ):
, where J is the correction factor.
Combining multiple outcomes within studies
Some studies in the current analysis utilised multiple scales to measure depression severity (HAMD, BDI, and MADRS). In such cases, the effect sizes d and their variance (V d ) were computed separately for each scale. Subsequently, one mean effect size d was computed/study using an arithmetic mean. The variance of such a mean effect size (V dmean ) was computed according to the following formula for combining multiple outcomes within the same studies (Borenstein et al. 2009 p. 227 
):
, where r=1.0 (correlation coefficient between outcomes in the same cases). Subsequent meta-analysis was computed on such a mean effect size of multiple outcomes/study and its variance.
Meta-analysis: random-effects model with inverse-variance weights
The weight in each study (W d ) was computed according to the random-effects model as follows (Borenstein et al. 2009 p. 73 
, where V d is the within-study variance (variance of d) and T 2 is the between-study variance which was computed according to the method of moments (or the DerSimonian and Laird method (DerSimonian and Laird 1986)) and using df=k-1 (k=number of studies) as follows (Borenstein et al. 2009 p. 73-74 
The overall mean weighted effect size (M d ) and its variance (V Md ) were computed for subgroups of studies as follows (Borenstein et al. 2009 p. 73-74): ( )
The lower and upper 95% confidence intervals of M d (LCI Md and UCI Md ) were computed as follows (Borenstein et al. 2009 p. 73-74): Finally, the z-score for M d was computed, to test the null-hypothesis that M d =0 meaning that rTMS is not effective at reducing depression scores compared to sham, according to the following formula (Borenstein et al. 2009 p. 74):
Computation of R 2 in meta-regression
Univariate linear meta-regressions were computed using the random-effects model to find out if the weighted effect sizes (outcome) could be predicted using the various study characteristics (clinical, demographic, and the rTMS parameters) in the current meta-analysis. The slope of the straight line (the line of best fit), B*, was tested for statistical significance according to the following formula (Borenstein et al. 2009 p. 197) :
The null-hypothesis tested was that B* is not different from zero (meaning that the predictor does not predict the outcome). Since univariate regressions were conducted (using one predictor only), it was assumed that the statistical significance of the slope of the regression line was equivalent to the statistical significance of the regression model.
The practical significance of the statistically significant regression models was tested using the equivalent of the R 2 index in linear regression. The formula for R 2 in meta-regression takes into account the between-study variance in the weighted d unexplained by the regression model containing the predictor (T 2 model shown as 'Tau-squared' in the output of the meta-regression module in CMA) and the total withinand between-study variance among the weighted d (T 2 total that is computed together with other heterogeneity statistics in the standard random-effects model of all studies involved in the meta-regression) as follows (Borenstein et al. 2009 p. 202 
The R 2 in meta-regression shows the proportion of the between-study variance in weighted d explained by the predictor. Notes: There were 55 sources in total because data from two abstracts excluded from the current analysis ( (Haag et al. 1997 ) and (Avery et al. 2000) ) were later included in published articles included in the current analysis ( (Padberg et al. 1999 ) and (Holtzheimer et al. 2004) ).
*Studies excluded from the current analysis (13/53 or 24% studies excluded). The exclusion criteria were:
• N=1: DLPFC not stimulated (vertex, Cz location, stimulated) (Kolbinger et al. 1995) • N=3: No sham group (Conca et al. 1996; Fitzgerald et al. 2008; Grunhaus et al. 2000) • N=2: Sham at location other than DLPFC: parietal cortex (active stimulation) (Herwig et al. 2003) , occipital cortex (active stimulation, coil tilted at 45°) (Moller et al. 2006) • N=1: Cross-over design used (Pascual-Leone et al. 1996) • N=5: Inadequate data reported and/or lack of response from authors:
 baseline scores for individual groups and after treatment scores missing (Lisanby et al. 2001)  parallel stimulation applied only after all participants received active stimulation and SD values for HAMD scores missing (Miniussi et al. 2005)  SD values for HAMD scores missing Stikhina et al. 1999)  after treatment HAMD28 scores missing (Szuba et al. 2001) • N=1: Depression secondary to stroke and SD values for HAMD scores missing (Jorge et al. 2004) Figure S1 Random-effects meta-analysis of N=40 studies Notes: The data shown on this figure are also included in the meta-analysis of N=54 studies (N=40 studies from this analysis and N=14 new studies) shown on Figure S3 ( Kedzior et al. 2014) . 'All' refers to all patients in multiple active rTMS groups who received rTMS with different parameters. 'Combined' in the column 'Outcome' indicates that more than one depression scale was used in a study and the effect sizes according to the multiple scales were combined into one. The mean number of patients per group was used in the final calculations if patients dropped out throughout the study between baseline and final sessions. The forest plot shows the weighted effect size d (box) and its 95% CI (vertical line through the box) for each study in the analysis. The diamond depicts the overall mean weighted d of all studies and its 95% CI (width of the diamond). The mean depression scores (baseline -final) were significantly reduced after rTMS compared to sham in 40 studies (overall mean weighted d=−.54, 95% CI: (2000) HAMD - 
